Cancer vaccine induces potent T cell responses — but is it enough?

Nature Reviews Clinical Oncology, Published online: 25 September 2020; doi:10.1038/s41571-020-00437-1Tumour-associated antigens are an attractive therapeutic target in immuno-oncology. Here, the exploratory analyses of T cell responses and preliminary clinical outcomes of the Lipo-MERIT trial of a melanoma vaccine are discussed in the context of prior efforts to harness the immunogenicity of such antigens for antitumour immunity.
Source: Nature Reviews Clinical Oncology - Category: Cancer & Oncology Authors: Source Type: research